305800-60-6

Basic information

• Product Name: 2-(5-bromo-2-fluorophenyl)acetonitrile
• Synonyms: 2-(5-bromo-2-fluorophenyl)acetonitrile;Benzeneacetonitrile, 5-broMo-2-fluoro-;5-Bromo-2-fluorobenzeneacetonitrile;5-Bromo-2-fluorobenzyl cyanide
• CAS NO: 305800-60-6
• Molecular Formula: C8H5BrFN
• Molecular Weight: 214
• Mol File: 305800-60-6.mol

Chemical Properties

• Appearance: /Solid
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 2-(5-bromo-2-fluorophenyl)acetonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(5-bromo-2-fluorophenyl)acetonitrile(305800-60-6)
• EPA Substance Registry System: 2-(5-bromo-2-fluorophenyl)acetonitrile(305800-60-6)

Safety Data

• HazardClass: 6.1
• Hazardous Substances Data: 305800-60-6(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
2-(5-bromo-2-fluorophenyl)acetonitrile is used as a building block for the creation of various complex organic molecules, contributing to the development of new chemical entities with potential applications in different industries.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 2-(5-bromo-2-fluorophenyl)acetonitrile is utilized as a key intermediate in the synthesis of drugs and pharmaceutical agents. Its unique structure allows for the development of novel compounds with potential therapeutic properties.
Used in Medicinal Chemistry:
2-(5-bromo-2-fluorophenyl)acetonitrile plays a significant role in medicinal chemistry, where it is employed as a reagent in the synthesis of bioactive molecules. Its presence in the molecular structure can influence the pharmacological properties of the resulting compounds, making it a valuable component in drug discovery and development.
Used in Specialty Chemicals Production:
As an intermediate in the production of specialty chemicals, 2-(5-bromo-2-fluorophenyl)acetonitrile contributes to the creation of high-value chemical products used in various applications, such as agrochemicals, dyes, and materials science.
Overall, 2-(5-bromo-2-fluorophenyl)acetonitrile is an important and versatile chemical with numerous potential applications across various industries, including organic synthesis, pharmaceutical research, medicinal chemistry, and specialty chemicals production. Its unique structure and reactivity make it a valuable asset in the development of new chemical entities and therapeutic agents.

Upstream product

• 99725-12-9 4-bromo-2-(bromomethyl)-1-fluorobenzene 

Downstream Products

• 615534-62-8 2-(5-bromo-2-fluorophenyl) ethan-1-amine 

Relevant articles and documents

Cyclocarbamate derivatives as progesterone receptor modulators

This invention provides compounds of Formula (I): wherein R1 and R2 may be single substituents or fused to form spirocyclic or hetero-spirocyclic rings; R3 is H, OH, NH2, C1 to C6 alkyl, substituted C1 to C6 alkyl, C3 to C6 alkenyl, substituted C1 to C6 alkenyl, alkynyl, or substituted alkynyl, CORC; RC is H, C1 to C3 alkyl, substituted C1 to C3 alkyl, aryl, substituted aryl, C1 to C3 alkoxy, substituted C1 to C3 alkoxy, C1 to C3 aminoalkyl, or substituted C1 to C3 aminoalkyl; R4 is H, halogen, CN, NO2, C1 to C6 alkyl, substituted C1 to C6 alkyl, alkynyl, or substituted alkynyl, C1 to C6 alkoxy, substituted C1 to C6 alkoxy, amino, C1 to C6 aminoalkyl, or substituted C1 to C6 aminoalkyl; and R5 is selected from a trisubstituted benzene ring of a five or six membered ring with 1, 2, or 3 heteroatoms from the group including O, S, SO, SO2 or NR6 and containing one or two independent substituents from the group including H, halogen, CN, NO2, amino, and C1 to C3 alky, C1 to C3 alkoxy, C1 to C3 aminoalkyl, CORF, or NRGCORF; or pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions and methods using the compounds as antagonists of the progesterone receptor.

Combination regimens using progesterone receptor modulators

This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure: wherein R1and R2may be single substituents or fused to form spirocyclic or hetero-spirocyclic rings; R3is H, OH, NH2, C1to C6alkyl, substituted C1to C6allyl C3to C6alkenyl, substituted C1to C6alkenyl, alkynyl, or substituted alknyl, CORC; RCis H, C1to C3alkyl, substituted C1to C3alkyl, aryl, substituted aryl, C1to C3alkoxy, substituted C1to C3alkoxy, C1to C3aminoalkyl, or substituted C1to C3aminoalkyl; R4is H, halogen, CN, NO2, C1to C6alkyl, substituted C1to C6alkyl alkynyl, or substituted alkynyl, C1to C6alkoxy, substituted C1to C6alkoxy, amino, C1to C6aminoalkyl, or substituted C1to C6aminoalkyl; and R5is selected from a trisubstituted benzene ring of a five or six membered ring with 1, 2, or 3 heteroatoms from the group including O, S, SO, SO2or NR6and containing one or two independent substituents from the group including H, halogen, CN, NO2, amino, and C1to C3alkyl, C1to C3alkoxy, C1to C3aminoalkyl, CORF, or NRGCORF; or pharmaceutically acceptable salt thereof. These methods of treatment may be used for contraception or for the treatment and/or prevention of secondary amenorrhea, dysfunctional bleeding, uterine leiomyomata, endometriosis; polycystic ovary syndrome, carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon, prostate, or inmization of side effects or cyclic menstrual bleeding. Additional uses of the invention include stimulation of food intake.